Article
Dermatology
Kamran Balighi, Cheida Shams-Davatchi, Salar Ghobadi, Maryam Daneshpazhooh, Vahide Lajevardi, Hamidreza Mahmoudi, Zeinab Aryanian, Amir Teymourpour, Ramtin Seirafi, Fereshteh Beigmohammadi, Soheil Tavakolpour
Summary: A retrospective study identified a subset of pemphigus patients with active lesions confined to the gingiva, who showed poor response to conventional treatments and rituximab therapy. Further studies on the pathogenesis of gingiva-confined presentation of pemphigus are needed.
DERMATOLOGIC THERAPY
(2022)
Article
Rheumatology
Mark E. McClure, Yajing Zhu, Rona M. Smith, Seerapani Gopaluni, Joanna Tieu, Tasneem Pope, Karl Emil Kristensen, David R. W. Jayne, Jessica Barrett, Rachel B. Jones
Summary: This study aimed to develop relapse and infection risk prediction models for patients with ANCA-associated vasculitis receiving rituximab maintenance therapy. While the models lacked the power to discriminate risk between individual patients, they were able to assign patients into risk groups, which may help guide decisions regarding the potential benefit of ongoing rituximab treatment. Prospective multi-centre validation studies are recommended before using these prediction models in practice.
Article
Dermatology
Bela J. Shah, Deval Mistry, Shikha R. Shah
Summary: Rituximab has been shown to have long-term efficacy and safety in the treatment of pemphigus. This retrospective analysis of 76 patients found that 82.7% achieved complete remission on or off therapy, with 35.5% experiencing relapse during follow-up. The use of rituximab can reduce the cumulative dose of prednisolone.
DERMATOLOGIC THERAPY
(2022)
Article
Rheumatology
Florence Delestre, Pierre Charles, Alexandre Karras, Christian Pagnoux, Antoine Neel, Pascal Cohen, Olivier Aumaitre, Stanislas Faguer, Pierre Gobert, Francois Maurier, Maxime Samson, Pascal Godmer, Bernard Bonnotte, Vincent Cottin, Catherine Hanrotel-Saliou, Thomas Le Gallou, Pierre-Louis Carron, Helene Desmurs-Clavel, Guillaume Direz, Noemie Jourde-Chiche, Francois Lifermann, Nicolas Martin-Silva, Gregory Pugnet, Thomas Quemeneur, Marie Matignon, Ygal Benhamou, Eric Daugas, Estibaliz Lazaro, Nicolas Limal, Maize Ducret, Antoine Huart, Jean-Francois Viallard, Eric Hachulla, Elodie Perrodeau, Xavier Puechal, Loic Guillevin, Raphael Porcher, Benjamin Terrier, French Vasculitis Study Grp FVSG
Summary: According to the results, the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. Further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Rodrigo Liberal, Rui Gaspar, Susana Lopes, Guilherme Macedo
Summary: The study evaluated the long-term efficacy and safety of MMF as a second-line therapy in AIH patients, showing that long-term use of MMF is safe and effective for AIH patients requiring second-line therapies.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
Article
Dermatology
Kamran Balighi, Parvaneh Hatami, Mohammad Javad Sheikh Aboli, Maryam Daneshpazhooh, Maryam Ghiasi, Hamid Reza Mahmoudi, Zeinab Aryanian
Summary: This study found that female patients with PV are older on average than male patients and require RTX treatment later in the course of their disease; RTX is effective in treating PV patients, with the therapeutic effect increasing with each cycle; Male gender, severe involvement of oral mucosa, and scalp and truncal lesions as initial cutaneous manifestations may indicate refractory PV.
DERMATOLOGIC THERAPY
(2022)
Article
Medicine, General & Internal
Pierre Larsson, Bodil Englund, Jana Ekberg, Marie Felldin, Verena Broecker, Lars Mjoernstedt, Seema Baid-Agrawal
Summary: This study retrospectively analyzed the data of 28 kidney transplant recipients who received everolimus-based quadruple therapy for difficult-to-treat rejections. The results showed a 5-year death-censored graft survival rate of 79% and a response rate of 43% in these patients. The 5-year patient survival rate was 94%. Despite some patients discontinuing treatment due to adverse events, this treatment approach may be effective for kidney transplant recipients with difficult-to-treat rejections.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Xiaochan Chen, Xiaowei Shi, Han Xue, Honghua Lv, Lishi Yu, Xiudi Wu, Qiaohong Wang, Huaxiang Wu, Fei Han, Jing Xue
Summary: This multicentre prospective cohort study demonstrates that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy.
Article
Allergy
Susanne J. van de Hei, Chong H. Kim, Persijn J. Honkoop, Jacob K. Sont, Tjard R. J. Schermer, Elaine MacHale, Richard W. Costello, Janwillem W. H. Kocks, Maarten J. Postma, Job F. M. van Boven
Summary: This study assessed the long-term cost-effectiveness of digital inhaler-based medication adherence management in difficult-to-treat asthma. The findings showed that digital inhalers can lead to cost savings in the long-term by optimizing medication adherence and inhaler technique and reducing add-on biologic prescriptions.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Urology & Nephrology
Dario Roccatello, Savino Sciascia, Carla Naretto, Mirella Alpa, Roberta Fenoglio, Michela Ferro, Giacomo Quattrocchio, Elena Rubini, Elnaz Rahbani, Daniela Rossi
Summary: In patients with biopsy-proven lupus nephritis, the intensified B-cell depletion induction therapy (IBCDT) without further immunosuppressive maintenance therapy showed comparable efficacy to conventional treatments, and was associated with a significant reduction in glucocorticoid cumulative dose.
KIDNEY INTERNATIONAL REPORTS
(2021)
Review
Dermatology
Shaghayegh Shahrigharahkoshan, Sahar Dadkhahfar, Nikoo Mozafari, Mohammad Shahidi-Dadras
Summary: Rituximab has shown significant efficacy in treating pemphigus patients but can lead to infectious events, among which viral agents are most commonly reported while bacterial agents are found to be the most fatal. Careful evaluation of the patients' medical profile before initiating rituximab therapy is necessary to identify any potential risk factors or predisposing conditions.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Burcin Cansu Bozca, Asli Bilgic, Soner Uzun
Summary: Rituximab appears to be effective for treating pemphigus, with 84.9% of patients achieving complete remission in this study. Additional rituximab cycles may help prolong remission in pemphigus patients resistant to conventional therapies. Prospective trials are needed to determine the optimal dosing protocol.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Multidisciplinary Sciences
Kailibinuer Abulikemu, Fengxia Hu, Junqin Liang, Xiaojing Kang
Summary: Pemphigus refers to a group of autoimmune skin disorders characterized by blistering, which can negatively impact quality of life. The current standard treatment involves the use of systemic corticosteroids and immunosuppressive agents, but their long-term use can lead to serious side effects. Therefore, researchers are exploring new and safer therapeutic approaches.
Article
Immunology
Josko Mise, Ines Lakos Jukic, Branka Marinovic
Summary: Pemphigus, an autoimmune disease, can be effectively treated with rituximab in Croatia according to this retrospective study. The majority of patients achieved complete or partial remission, but relapse rates were high.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Roba Ghossan, Omar Al Tabaa, Alice Combier, Alexia Steelandt, Marion Thomas, Olivier Fogel, Corinne Miceli-Richard, Anna Molto, Yannick Allanore, Jerome Avouac
Summary: Maintaining complete B cell (BC) depletion does not appear to be a therapeutic target to achieve in rheumatoid arthritis (RA) patients in long-term maintenance therapy with rituximab (RTX).